Similar articles

• Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.

  Moltó J, Ruiz L, Valle M, Martinez-Picado J, Bonjoch A, Bravo I, Negredo E, Heilek-Sneider GM, Clotet B. Moltó J, et al. Antivir Ther. 2006;11(1):47-51. Antivir Ther. 2006. PMID: 16518959 Clinical Trial.
• Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

  Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group. Joly V, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19. Antimicrob Agents Chemother. 2013. PMID: 23165467 Free PMC article. Clinical Trial.
• An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.

  Pierone G Jr, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, Fontaine L, Fath M. Pierone G Jr, et al. AIDS Patient Care STDS. 2008 Apr;22(4):263-6. doi: 10.1089/apc.2007.0148. AIDS Patient Care STDS. 2008. PMID: 18422459 Clinical Trial. No abstract available.
• The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

  Chetchotisakd P. Chetchotisakd P. Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66. Expert Rev Anti Infect Ther. 2009. PMID: 19735222 Review.
• An update and review of antiretroviral therapy.

  Piacenti FJ. Piacenti FJ. Pharmacotherapy. 2006 Aug;26(8):1111-33. doi: 10.1592/phco.26.8.1111. Pharmacotherapy. 2006. PMID: 16863488 Review.